CLINICAL FEATURES AND PROGNOSTIC ANALYSIS OF PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA AND HEPATITIS B VIRUS INFECTION
Objective To investigate the relationship between hepatitis B virus (HBV) infection and B-cell non-Hodgkin's lymphoma (B-NHL),and to analyze the clinical features and prognosis of B-NHL patients with HBV infection.Methods A total of 345 B-NHL patients were divided into hepatitis B surface antigen (HBsAg)-positive group (n =65) and HBsAg-negative group (n =280).The clinical features and prognosis of the patients in the two groups were analyzed and the HBsAg-positive rate was compared between the 345 B-NHL patients and the general population in China.Results The HBsAg-positiverate in the 345 B-NHL patients was significantly higher than that in the general population in China (18.8% vs 7.2%,P<0.001,binomial test).Compared with the HBsAg-negative group,the HBsAg-positive group had a significantly younger median age of onset (t=5.675,P<0.01),significantly higher incidence of involvement of the liver,spleen,or retroperitoneal lymph node (x2 =6.216-10.137,P<0.05),a significantly later stage of disease (Ⅲ/Ⅳ) (x2 =9.771,P<0.05),and a significantly worse prognosis (x 2 =4.748-8.300,P <0.05).Univariate analysis showed that the poor prognostic factors for the patients in the HBsAg-positive group were B symptoms,Ann Arbor staging (Ⅲ/Ⅳ),increased β2-microglobulin level,not combined with rituximab,and not combined with radiotherapyd (x2 =3.860-26.767,P<0.05).Multivariate analysis showed that the poor prognosis was associated with B symptoms,Ann Arbor staging (Ⅲ/Ⅳ),and not combined with rituximab (95%CI=0.170-31.746,P<0.05).Conclusion The HBV infection rate in B-NHL patients is significantly higher than that in the general population in China.B-NHL patients with HBV infection have unique clinical manifestations and relatively poor prognosis and rituximab can improve the prognosis of B-NHL patients with HBV infection.
B-cell non-Hodgkin lymphomahepatitis B virusprognosis